 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 1 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
Study Protocol 
Clinical Study Evaluating the Safety of PregSense ™ and Comparative 
Performance of PregSense™ versus CTG in Prenatal Monitoring of Pregnant 
subjects  
 
 
 
Protocol  Number:  CLP1000  
 
Test Product:  PregSenseTM  
Sponsor's Name:  
[CONTACT_2728]'s Address:  Nuvo Group  Ltd. 
11th Menachem Begin Rd., Ramat Gan  5268104, 
Israel  
Sponsor’s Telephone Number:  
Sponsor’s Fax Number:  Tele# (+972).3.624.2266  
Fax#  (+972).3.529.4072  
Study Number and version : 
Version Date:  CLP1000  rev #[ADDRESS_259434]/Ethics Committee approval, informed consent and the approval 
of local regulatory authorities as required by [CONTACT_1769].  
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 2 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
Approval Table : 
 Name  [CONTACT_215702]  [CONTACT_215653] & RA    
Reviewed and 
Approved by  [CONTACT_215654] : 
Revision No.  Description of Changes  Release date  
[ADDRESS_259435] signature [CONTACT_568]  
02 • Updates to Standard s 
• Update Illustrations & block diagrams  
• Statistical  analysis update  
• Presentation App – MD output  
• Editorial changes  
• Additional table of figures  
• Additional appendix -  Pi[INVESTIGATOR_215629]  
03 • Update Presentation App output  (page 22 -23) Same as last signature [CONTACT_568]  
04 • Change Pi[INVESTIGATOR_215630]  
• Screening update (section 5.1.1)  
• Recording session update  (section 7.2)  
• Statistical analysis update (sections 9)  
• Editorial changes  Same as last signature [CONTACT_568] 
05 • Statistical analysis update following FDA 
recommendation (section 9)  
• The term "gold standard" was changed to 
"standard of care" as per FDA request.  
• Increased the number of blinded assessors from 2 
to 3 regardless discrepancy of assessment  
• Removed UA from intended of use and kept it in 
the secondary end -point for data collection 
purpose   
• Editorial changes  Same as last signature [CONTACT_215703][INVESTIGATOR_014]:  
# Location  
Master  Clinical Files  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 3 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
 
Investigators' Statement  
I have read the protocol:  
 
Clinical Study Evaluating the Safety of PregSense™ and Comparative 
Performance of PregSense™ versus CTG in Prenatal Monitoring of Pregnant 
subjects  
 
That contains all information necessary to the conduct of the study. I agree to conduct the study as outlined 
therein and in accord ance with  ISO [ADDRESS_259436] the study under the conditions described in this protocol:  
 
 
________________________________                                                 |__| |__| / |__| |__| /  |__| |__|  
      Principal  Investigator (Print Name)                                  Date         (dd / mm / yy)  
 
                                                                   
 
     Principal Investigator's Signature  
 
[CONTACT_2761]:  
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 4 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
TABLE OF CONTENTS  
1 INTRODUCTION  .............................................................................................................................................. 13 
1.1 BACKGROUND  ..................................................................................................................................................... 13 
2 STUDY RATIONALE  ........................................................................................................................................ 14 
3 DEVICE DESCRIPTION ................................................................................................................................... 15 
3.1 INTENDED USE ..................................................................................................................................................... 15 
3.2 DATA FLOW DIAGRAM BET WEEN THE MAIN COMPONENTS OF PREGSENSE ™: ..................................................... 15 
3.3 THE SYSTEM  ........................................................................................................................................................ 17 
3.3.1  Wearable device .......................................................................................................................................... 18 
3.4 CLOUD  .................................................................................................................................................................  20 
3.4.1   Transport Layer & Raw data management  ................................................................................................ 20 
3.4.2  Data Processing .......................................................................................................................................... 20 
3.5 MOBILE APPLICATION (MA)  – GATEWAY SERVICE APPLICATION  ....................................................................... 21 
3.5.1  MD Application:  ........................................................................................................................................ 22 
3.5.2  Mom Application:  ...................................................................................................................................... 22 
3.6 DEVICE SAFETY - COMPLIANCE PRE-CLINICAL  .................................................................................................... 23 
3.6.1  Compliance and Pre -Clinical ..................................................................................................................... 23 
3.6.2  Previous Clinical evaluation  ....................................................................................................................... 23 
3.7 RISK MANAGEMENT ANALYSIS  ............................................................................................................................ 24 
4 STUDY ENPOINTS  ........................................................................................................................................... 24 
4.1 PRIMARY PERFORMANCE ENDPOINTS : ................................................................................................................. 24 
 BOTH ENDPOINTS WILL B E COLLECTED VIA PREGSENSE ™ AND VIA THE STANDAR D OF CARE MONITORING  SYSTEM 
(CTG).  ............................................................................................................................................................................. 24 
4.2 SAFETY ENDPOINTS : ............................................................................................................................................ 24 
4.3 SECONDARY PERFORMANCE ENDPOINTS : ............................................................................................................ 24 
 ......... CONTRACTIONS WILL BE COLLECTED VIA PREGS ENSE™ AND VIA THE STANDARD OF CARE  
MONITORING SYSTEM (C TG).  ............................................................................................................................. 24 
5 STUDY DESIGN  ................................................................................................................................................ 24 
5.1 STUDY OVERVIEW AND PLAN  .............................................................................................................................. 24 
5.1.1  Screening  .................................................................................................................................................... 24 
5.1.2  Recording session ....................................................................................................................................... 25 
5.2 EARLY DISCONTINUATION  ................................................................................................................................... 25 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 5 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
5.2.1  Criteria for Early Discontinuation .............................................................................................................. 25 
5.2.2  Sponsor’s Termination of Study  .................................................................................................................. [ADDRESS_259437] ELIGIBILITY  .................................................................................................................................. 26 
6.1 INCLUSION CRITERIA : .......................................................................................................................................... [ADDRESS_259438]  ............................................................................................................................................ 26 
7.1 SCREENING & ENROLLMENT  ............................................................................................................................... [ADDRESS_259439] OF CARE ............................................................................................................................................ 28 
7.4 CONCOMITANT TESTS , THERAPY AND TREATME NT .............................................................................................. 28 
7.5 END OF STUDY /COMPLETION OF STUDY  ............................................................................................................... 28 
8 ASSESSMENT OF SAFETY  ............................................................................................................................. 28 
8.1 SAFETY PARAMETERS  .......................................................................................................................................... 28 
8.2 ADVERSE EVENTS  ................................................................................................................................................ 28 
8.2.1  Severity definition:  ...................................................................................................................................... 29 
8.2.2  Relationship of an adverse event to the Treatment/ Device  ........................................................................ 29 
8.3 ADVERSE EVENTS (AE)  AND SEVERE ADVERSE EVENTS (SAE)  REPORTING  ...................................................... 29 
9 STATISTICAL CONSIDER ATIONS  ................................................................................................................ 30 
9.1 STUDY DESIGN AND OBJECTIVES  ......................................................................................................................... 30 
9.2 STUDY ENDPOINT MEASURES  .............................................................................................................................. 30 
9.2.1  Primary Performance Measures  ................................................................................................................. 30 
9.2.2  Safety Endpoint Measures  ........................................................................................................................... 30 
9.2.3  Secondary Performance Measures  ............................................................................................................. 30 
9.3 SUCCESS CRITERION  ............................................................................................................................................ 30 
9.4 SAMPLE SIZE JUSTIFICATION  ............................................................................................................................... 30 
9.5 DATA ANALYSIS SETS ......................................................................................................................................... 31 
9.5.1  Performance Analysis Set (PA)  ................................................................................................................... 31 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 6 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
9.5.2  Statistical Analysis of Analysis Sets  ............................................................................................................ 31 
9.6 STATISTICAL ANALYSIS  ....................................................................................................................................... 31 
9.6.1  General Considerations  .............................................................................................................................. 31 
9.6.2  Demographic and other baseline variables  ................................................................................................ 32 
9.6.3  Disposition of subjects  ................................................................................................................................ 32 
9.6.4  Performance analysis  .................................................................................................................................. 32 
9.6.5  Pooling  ........................................................................................................................................................ 33 
9.6.6  Handling of missing data  ............................................................................................................................ 33 
10 STUDY MONITORING & Q UALITY ASSURANCE AUDITS / INSPECTIONS  ...................................... 33 
10.1 GOOD CLINICAL PRACTICE  .................................................................................................................................. 33 
10.2 MONITORING PROCEDURES  .................................................................................................................................  33 
10.3 QUALITY ASSURANCE PROGRAM  ........................................................................................................................ 34 
10.4 REGULATORY INSPECTIONS  .................................................................................................................................  34 
11 USE OF INFORMATION A ND PUBLICATION  ......................................................................................... 34 
11.1 CONFIDENTIAL INFORMATION  ............................................................................................................................. 34 
12 ETHICAL AND LEGAL AS PECTS  .............................................................................................................. 34 
12.1 COMPLIANCE WITH REGULATIONS APPLICABLE TO CLINICAL TRIALS  ................................................................ 34 
12.2 INFORMED CONSENT  ........................................................................................................................................... 35 
12.3 ETHICS COMMITTEE (EC)  / INSTITUTIONAL REVIEW BOARD (IRB) ..................................................................... [ADDRESS_259440]  ................................................................................................................. 37 
14.1 SUPPLY AND DISPOSITION OF STUDY DEVICES  .................................................................................................... 37 
14.2 DEVICE ACCOUNTABILITY  ................................................................................................................................... 37 
15 APPENDICES ................................................................................................................................................. 39 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 7 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
15.1 APPENDIX 1 –RECORDING SESSION FLOW  ........................................................................................................... 39 
15.2 APPENDIX 2 – PI[INVESTIGATOR_215631]  ............................................................................................ 40 
15.3 APPENDIX 3 – PI[INVESTIGATOR_215632]  ....................................................................................................... 41 
16 REFERENCES  ............................................................................................................................................... 42 
Table of figures:  
Figure 1 PregSense ME (self -monitoring)  ............................................................................................................... 15 
Figure 2 PregSense MD (remote monitoring)  .......................................................................................................... 16 
Figure 3  PregSense MD (Medical center/Clinic environment)  .................................................................................. 16 
Figure 4 Block Diagram of PregSenseTM Components  ............................................................................................. 17 
Figure 5 Schematic Illustration of the Wearable Sensory Belt  .................................................................................. 19 
Figure 6  PregSense data flow of the cloud  ............................................................................................................. 20 
Figure 7 PregSense d ata flow from the cloud to the App  .......................................................................................... 21 
Figure 8 Recording Session Flow  .......................................................................................................................... 39 
Figure 9 Pi[INVESTIGATOR_215633] ................................................................................................................. 40 
Figure 10 Pi[INVESTIGATOR_215634]:  ........................................................................................................... 41 
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 8 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
STUDY SYNOPSIS  
Protocol Number  CLP10 00 
Study Title : Clinical Study Evaluating the Safety of PregSense™ and Comparative 
Performance of PregSense ™ versus CTG  in  Prenatal Monitoring of  Pregnant 
subjects.  
Number of 
Centers : Up to 5 centers  with possible extension  
Countries : Israel , [LOCATION_013]  and [LOCATION_003]   
Study Duration :  The expected total duration of the study for each subject is up to 2 hours  as 
follows:  
Enrollment: Gestational age > 32+0  weeks 
Data collection: 1st data collection session and optional additional sessions 
between the initial session and up to labor .  
Total  Study 
Duration : ~[ADDRESS_259441] 
Enrollment : The total expected enrollment is up to [ADDRESS_259442] s.   
Study Population : Pregnant women with singleton gestation > 32+0 weeks of pregnancy.   
Study Objectives : The primary objective of th is research is to assess the agreement between 
PregSenseTM data collection, and values measured via the standard of care used 
for prenatal monitoring (i.e. CTG)  and to assess the safety of PregSense™ . 
Study Design : This will be a multi -center, prospective, comparative, open label  study . 
 Screening:  
Confirmation of the eligibility criteria will be performed. Eligible subject s will be 
included into the study. 
• Consent and recruitment  
• Subject preparations  
• The sensors will be attached on the subject 's abdomen 
Recording session:  
The subject will undergo continuous recording using PregSense.  
Additional recording with the standard of care (CTG  - Cardiotocography) will be 
done , including, but not limited to, ECG  (Electrocardiogram ), non-stress test and 
uterine contractions recording .  
In addition (if applicable), clinical tests, clinical scores, medications, fluids and 
imaging data and its interpretation will be collected . 
Offline analysis:  
The data will be collected and downloaded. C omprehensive analysis of the values 
will be performed offline.  
Safety assessment:  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259443] will undergo continuous monitoring by [CONTACT_215655], including but not limited to, irritation, sensitization and potential 
harmful misuse.  
Inclusion criteria : 1. Female age between  18-50 
2. Gestational age > 32 + 0  weeks  
3. Singleton gestation  
4. Ability to understand and sign informed consent  
Exclusion criteria : 1. BMI ≥45 and 15≤ prior pregnancy  (Body Mass Index)  
2. Multiple gestation  
3. Uncontrolled Hypertension  
4. Fetal Anomaly  
5. Subjects with skin problems in the abdominal area  (such as flesh wounds, 
cuts in the skin, skin rash es, etc.)  
6. Subjects with implanted electronic devices (pacemaker, defibrillator, etc.)  
7. Subjects who, in the judgment of the inves tigator, are likely to be non-
compliant or uncooperative during the study  
Medical Device 
Description :  PregSense ™, developed and designed by [CONTACT_215656] , consists of the following 
three basic components:  
(1) Wearable device –  containing;  
a. The sensors module ( WSB - Wearable Sensory  Belt)  
b. The major electronic module (WSH -  Wireless Sensing Hub)  
(2) Mobile Application (MA) –   
a. Gateway Service App lication  
b. Presentation App lication : 
i. MD App lication : 
ii. ME App lication : 
(3) Cloud based application  
PregSense ™ will include the following features  [Please note, in PregSense Apps  
(ME, MD or Pi[INVESTIGATOR_215635]) the features might be presented in alignment 
with the end user requirements ]:  
• FHR (Fetal Heart Rate)   
• MHR  (Maternal Heart Rate)   
• Fetal heart rate response ( Fetal Activity ) (in PregSense ME App)  
• Maternal Activity (in PregSense ME App)  
• Uterine Activity (Uterine Contractions , if applicable)   
Note: For this Pi[INVESTIGATOR_2397], a subversion of the Application with  study metrics 
only will be applied , in order to show the agreement between PregSense and the 
standard of care device (i.e. CTG) . 
Study Endpoints : Primary  Performance Endpoints : 
• Fetal HR   
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 10 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
 
  • Maternal HR  
 
Safety Endpoints:  
• Safety, tolerability and compliance with PregSense™ in pregnant 
women with singleton pregnancy > 32 + 0 weeks of gestation.   
• All adverse events and serious adverse events related and unrelated 
to PregSense use.  
As collected via PregSense™  and the data collected via the standard of care 
monitoring system (i.e. CTG). 
Secondary Performance Endpoints:  
• Uterine contractions  
As collected via PregSense™  and the data collected via the standard of care 
monitoring system (i.e. CTG). 
 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259444] – Adverse Device Reaction  
AE – Adverse Event  
APP - Proprietary Mobile Application  
BMI – Body Mass Index  
BT- Bluetooth  
CCM - Cloud Computing Module  
CE - European Conformity   
CL – Cervical Length  
CRC – Clinical Research Coordinator  
CRF – Case Report Form  
CTG – Cardiotocography  
DPE -  Data Processing Engine  
EC/IRB –Ethic Committee/Institution Review Board  
ECG – Electrocardiogram  
EEG – Electro - Encephalography  
EHG - Electrohysterography  
EMG – Electromyography  
EUM – Electrical Uterine Myography  
FCC - Federal Communications Commission  
FDA – Food and Drug Administration  
FHR – Fetal Heart Rate  
FSE – Fetal Scalp Electrode  
HW – Hardware  
HIPAA - Health Insurance Portability and Accountability Act  
LOA -  Limits of Agreement  
ICF – Informed Consent Form  
IP – Investigational Product  
IUPC – Intrauterine Pressure Catheters  
MA – Mobile Application  
MD – Medical Doctor  
ME – Management Engine  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 12 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
MHR – Maternal Heart Rate  
NST – Non-Stress Test  
PA – Performance Analysis  
PCG - Phonocardiography  
PI – Primary Investigator  
RTTI - Run-Time Type Information  
SA – Safety Analysis  
SW – Software  
TOCO – Tocodynamometry  
UA – Uterine Activity  
UC – Uterine Contractions  
US – Ultra Sound  
WSB – Wearable Sensory Belt  
WSH – Wireless Sensory Hub  
 
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 13 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
1 INTRODUCTION 
1.1 Background  
Pregnancy brings a variety of health risks to women as well as to their unborn child. In the US, among the ~ 4 
million deliveries  each year, 94.1% list some type of pregnancy complication1.  Complications and pregnancy 
symptoms  range from mild and annoying discomforts to severe illnesses, sometimes even life-threatening . There 
are times when where it is difficult for a woman to determine which symptoms are normal and which are not23. 
Pregnant women have  limited opportunities to  expand their  understand ing of their  fetus’s development in utero. 
Besides the monthly checkups with their doctor, pregnant women will remain unaware of their fetal’s  activities .   
The mother wants information, comfort and the confidence that she is doing everything she can to complete a 
healthy  pregnancy and to create additional opportunities to learn about and bond with her developi[INVESTIGATOR_16103] .  
Secondarily, mother herself is going  through many physiological changes that result in differing sleepi[INVESTIGATOR_215636], activity levels, and sleep cycles. Importantly, she wants to know how her activities impact her developi[INVESTIGATOR_16103]
4.   
Current clinical assessment of potential fetal distress dur ing pregnancies is done through in- frequent monitoring 
of the vital signs of mother and unborn child. Existing technologies e.g. Ultra Sound (US)  Doppler us, are used 
in an out -clinical setting and in some cases in a clinical setting. None of these technol ogies are used 
continuously. Also, these technologies typi[INVESTIGATOR_215637] (e.g. cardiac state), do not occur in real -
time and involve survey -based  information from the mother. The fetal heart rate is currently the standard of care  
to tell whet her the fetal  is doing well or may have some problems.  
In addition, the poor inter -and intra - observer variabilities in the interpretation of FHR tracing have been known 
as one of the major drawbacks of the CTG monitoring5. For example, when 4 obstetricians examine 50 CTGs, 
the agreement was reported as only 20% of the cases6. The visual interoperation of CTG traces seems to be a 
major cause.  Computerized CTG is a method to analyze FHR patterns in terms of a computer algorithm to improve CTG in terpretation by [CONTACT_215657] -observer.  
 
Doppler -based technology has been the  standard of care in pregnancy monitoring for 40+ years, influencing 
the vast majority of home pregnancy monitors available today. Wearable health technology ha s become much 
more prevalent in everyday lives, with companies like FitBit, Pebble, Jawbone, and  Apple Watch paving the 
way for personal health and wellness trackers as commonplace devices. However, a viable and accurate 
wearable pregnancy solution that does not use Doppler -technology, and can therefore be used safely and 
continuously, is not yet on the market. 
There are two types of monitoring -external and internal as standard of care:  
External Monitoring:  External monitoring is usually being done at different times during the pregnancy, and/ or 
during labor.  
External monitoring can be done by [CONTACT_215658] a stethoscope. More often, external 
monitoring is done using two flat devices  (sensors) held in place with elastic belts on the belly. One sensor uses 
reflected sound waves (ultrasound) to keep track of the FHR . The other sensor measures the contractions 
                                                      
[ADDRESS_259445]: Complicating Conditions of Pregnancy and Childbirth, 2008  
2 Pregnancy Complications; Centers for D isease Control and Prevention  
3 If You Do Not Ask, They Will Not Tell: Evaluating Pregnancy Risk in Young Women in Pediatric Hospi[INVESTIGATOR_600]: Journal of 
Adolescent Health  
4 Fetal Monitoring: Creating a Culture of Safety With Informed Choice  
5 Inconsistencies in classification by [CONTACT_215659].  
6 Intra - and inter -observer variability in the assessment of intrapartum cardiotocograms .  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259446]  (NST) , which records the fetal heart rate while the 
fetal is moving and not moving. The pri mary goal of the test is to measure the heart rate of the fetus in response 
to its own movements. Healthy babies will respond with an increased heart rate during times of movement, and 
the heart rate will decrease at rest. The concept behind a non -stress t est is that adequate oxygen is required for 
fetal activity and heart rate to be within normal ranges.  
A non- stress test may be combined with a fetal ultrasound to evaluate the amount of amniotic fluid.  
External monitoring is also done for a contraction str ess test  (CST) , which records changes of the fetal heart 
rate during uterine contractions. It is performed near the end of pregnancy to determine how well the fetus will 
cope with the contractions of childbirth. The aim is to induce contractions and monitor the fetus to check for 
heart rate abnormalities using a cardiotocograph. A CST is one type of antenatal fetal surveillance technique.  It 
may help predict the fetal capability to tolerate the stress of labor and vaginal delivery7. 
The biggest advantage of Cardiotocography (CTG) is that it is an external device. The disadvantage is its 
inability to give an accurate reading on intrauterine pressure and activity . Without intrauterine pressure 
capability the CTG is not an indicated device for augmentation of labor. The CTG’s readings can not only be 
influenced by [CONTACT_90169] -amniotic pressure but by [CONTACT_215660], etc. It is 
hampered by [CONTACT_215661], which is why there is a high rate of fail ure in high BMI Moms.  
Overall, in high BMI moms the accuracy in CTG is poor. Furthermore, the best position for CTG is supi[INVESTIGATOR_050], 
which is not desirable for the subject  and limits mobility. The technology has remained essentially unchanged 
since 1968.  
Interna l monitoring ; “Intrauterine pressure catheters (IUPC) and fetal scalp electrodes (FSE) are commonly 
used devices for intrapartum monitoring and management. Although the internal monitors used are sterilely 
packaged, they travel through the vaginal canal in to the uterine cavity, providing a potential pathway for 
contamination and ascending infections8. 
Internal  monitoring can be done only after the cervix has dilated to at least 2 centimeters (cm) and the amniotic 
sac has ruptured  and if the ECG cannot be pe rformed  as part of the routine gold standard.  
 
2 STUDY RATIONAL E 
PregSense ™ provides accurate, real -time and continuous information on fetal  and maternal parameters, without 
compromising the subject ’s and fetus’s safety. Application and set -up take only minutes, shortening the time of 
data collection.  The non– invasive PregSense ™ brings a much -awaited  breakthrough in the field of maternity 
monitoring.  
PregSense ™ is based on measurements of fetal and maternal wellbeing including: fetal movements, maternal  
& fetal cardio -vascular activity and uterine contractions . The clinically validated mature wearable system will 
simultaneously record both fetal and  maternal parameters non -invasively for extended periods of time. The 
product provides robust parameter measurements compared to the standard of care monitoring device for home 
use. 
                                                      
7 Fetal Heart Monitoring: John Hopkins Medicine  
8 External and Internal Heart Rate Monitoring of the Fetus: University of [COMPANY_002]ster School of Medicine  
 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 15 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
3 DEVICE DESCRIPTION 
3.1 Intended Use  
PregSense ™ is a maternal -fetal monitor that non -invasively measures and displays fetal heart rate (FHR ) 
and maternal heart rate (MHR). PregSense ™ acquires and displays the FHR & MHR tracing from 
abdominal surface electrodes that pi[INVESTIGATOR_215638] (fECG) and mate rnal ECG (mECG) signal, and 
surface acoustic sensors that pi[INVESTIGATOR_215639] (fPCG) and the maternal PCG (mPCG) signals.  
PregSense ™ is indicated for use on women who are >32 gestational  weeks, with singleton pregnancies, 
using surface electrodes on the maternal abdomen. PregSense ™ maternal -fetal monitor  is intended for 
use by [CONTACT_215662]’ home on the 
order of a physician.  
This system does not prevent the onset of preterm labor no r will it prevent the occurrence of preterm 
birth.  
Intended population:  
• Pregnant women with a singleton pregnancy > 32 + 0  weeks of  gestation.  
 
3.2 Data flow diagram between the main components of PregSense ™:  
 
 
Figure 1 PregSense ME ( self-monitoring)  
 

 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 16 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
Figure 2 PregSense MD (remote monitoring)  
 
Figure 3 PregSense MD ( Medical center/Clinic  environment ) 
  

 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 17 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
3.3 The system  
 
Figure 4 Block Diagram  of PregSenseTM Components  
 Acoustic 
Sensors
Bio-potential 
Sensors (ECG)
Motion sensing moduleWSH
User Interface module
Power Source
Battery Management module
Wir eless / BT commu nicatio n 
modu le
Memory
modu le
Security & Authentication
  
(Wearable Sensory Belt)
Textile Belt
Microcontroller UnitSensors
Belt
         
 
         Transport Layer Algo ServerAuthentication Layer
(Users/ FM Sessions / 
Devices / Services)Security/ 
Encrypted / Cyber
Raw Data 
DBProcessed 
Data DBUser DataCLOUD
On boarding:
• User registration
• Basic Info
• Login
“Gateway ”     WSH↔  App ↔ Cloud
(Communication & Device management)
Error handling      App ↔ Cloud 
(quality of skin-sensors attachment )GATEWAY App
I / O   
Device management
Session managment
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 18 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
PregSense ™ - developed and designed by [CONTACT_215663]., consists of the following three main 
components : 
(3) Cloud based application  
3.3.1 Wearable device  
The Wearable device  incorporates wearable sensors and electronics for data acquisition, data storage and 
communication.  
The Wearable device  contains the following compartments:  
[IP_ADDRESS]  Wearable Sensory Belt ( WSB ) 
The passive , non-invasive  sensors located on the abdomen above and below the womb and held in 
position by [CONTACT_215664], expandable and adjustable textile straps.  
The Wearable S ensory  Belt is composed of 2 elements:  
a. Textile Belt  (see figure 2) : 
The textile belt is designed to allow good attachment of sensors to the woman’s abdomen and for 
maximum comfort; its adjustable circumference range is approximately 60 -150 cm.  
b. Sensors : 
The sensors are divided into 2 types; Acoustic and Bio -potential.  
§ Acoustic  - The acoustic sensor was developed and designed by [CONTACT_215663]., and  for maximum 
patient safety , the electrical parts are isolated from the patients’ body. The acoustic sensors are 
essentially highly sensitive components  transducing acoustical  pressure into electrical voltage.  The 
sensors ’ acoustic properties are designed for maximum performance. The inner microphone is carefully 
selected to match the working environment. I t replicates the  concept of electronic stethoscope, but rather  
than using a single sensor that can not follow fetal movements in the womb, there  are four sensors 
symmetrically distributed in four locations on upper and lower parts of the abdomen – two on each side 
– attach ed to the body with the textile belt.  
§ Bio-potential  - The bio- potential sensor was developed and designed by [CONTACT_215663]. for collecting 
the electrical signals from the skin with maximum patient safety and comfort  in a manner that resembles 
ECG , enabli ng continues recording of the electrical activity of the heart . These sensors  detect the tiny 
electrical changes on the skin that arise from the heart muscle's electro -physiologic al pattern of 
depolarizing during each heartbeat. The measured signals are the potential difference between two 
selected points on the body, called " leads".  
The bio- potential signals com e from the subject ’s heart and mainly the fetus ’s heart. However, due to 
their sizes and streng th, the bio- potential signals coming from a given  subject ’s heart are three orders of 
magnitude (i.e. 1,000  times ) stronger than the fetus ’ signals. The maternal and fetal  heartbeats are not (1) Wearable device containing ; 
a. The sensors module ( WSB- Wearable S ensory  Belt)  
b. The major electronic module ( WSH  - Wireless Sensing Hub) . 
(2) Mobile Device Application (MA) ; 
a. Gateway Service App lication  
b. Presentation App lication : 
i. MD App lication  
ii. ME App lication  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 19 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
synchronized, and typi[INVESTIGATOR_215640]  (about twice) than the heartrate of the 
pregnant subject.  
The shape of the sensor suits the pregnant woman’s abdom inal curvature . The bio- potential sensor is 
designed to maximize the contact [CONTACT_215665] a high -quality  signal.  
 
Figure 5 Schematic Illustration of the Wearable Sensory Belt  
 
 
 
 
 
 
 
  
View A –I nner view of the PregSense ™ Wearable Sensory B elt, 
View B – Outer view of the PregSense™  Wearable Sensory B elt 
 
[IP_ADDRESS]  Wireless Sensing Hub (WSH)  
The WSH intends to acquire the signals from the sensors, transform it and transmit it to a nearby 
[CONTACT_10753]/Tablet.  
The module consists of three main parts: A nalog Front-End Module  (AFEM) , Analog -to-Digital 
Conversion M odule  (ADCM)  and Wireless Communica tion M odule  (WCM) . The AFEM  provides 
initial signal conditioning , including  impedance matching, amplification , and bandwidth filtering. 
The module further – ADCM incorporates the Analog to Digital Converter  which converts the data 
from analog to digital do main and then a Wireless Communication Module which transfers the data 
to a nearby (up to 10 meters) mobile device ( smartphone  or tablet ) using Bluetooth® technology . 
The module, as the rest of the product, complies  with FCC, CE and RTTI standards.  

 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 20 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
PregSense ™ is powered by a rechargeable battery  and equipped with a battery charger  cable. 
PregSense ™ is not operable while charging the battery. 
  
 
 
 
Figure 6  PregSense data flow of the cloud  
3.4 Cloud  
Cloud- based modules , which includes also data -bases management, are running on servers operated by a major 
cloud service provide r, such as Amazon Web Services by [CONTACT_215666]. or similar. It leverages the essential 
services provided by [CONTACT_215667], such as security, privacy, redundancy, scalability , etc.  
This  component receives the data from the  PregSense  Mobile A pplication (MA) and performs the proprietary 
signal processing.  
   
3.4.1  Transport Layer & Raw data management  
This module handles the incoming raw data  and meta -data from the MA by  [CONTACT_215668], 
including completing missing data due to communication errors, and stores the data in Raw Datab ase Meta -data 
includes, but not limited to;   
a) user -name [CONTACT_215704]  
b) belt UDI  
c) WSH – Mac address  
d) time tag (for all stored data) -  year, month, day, hour, minute, second (of each session form the first 
session start to last session end)  
 
3.4.2 Data Processing   
The cloud receives the data from the application (MA) and performs the proprietary signal processing , 
which leads to a clear fetal and maternal cardiac activity  signal and uterine contractions  signal. Merging 
(or fusion) of the outcome of the Bio- potential (after processing) and the acoustic 
sensors/Phonocardiogram (PCG) (after processing) is performed by [CONTACT_215669]. T he algorithm enable s the inference of the Fetal Hea rt Rate (FHR ). 

 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 21 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
CLOUD  
 
 
 
 
MD  Services:
• Values: UA, FHR, MHR
• Graphs (CTG like)
• Basic Analytic
• Ranges references (ACOG)
• Customized/ personal setting 
alerts
• Telemedicine PRESENTATION App
Mom Services:
• Average:  FHR, MHR
• Uterine Contractions
• Fetal heart rate response 
(fetal activity)
• Maternal activity
• TelemedicinePRESENTATION App
 
Figure 7 PregSense data flow  from the cloud to the App 
 
3.5 Mobile Application (MA) – Gateway Service App lication  
The MA  transfers a combined sensor y data from the Wearable Device in real -time to the cloud for processing. 
The role of this part of the system  is to handle the data communication between the Wearable Device and the 
Cloud verify ing that the information is received properly and safely , assur ing continuous reliable connection 
with minimum interruption .  
A tablet /smartphone typi[INVESTIGATOR_215641]: a) Bluetooth b) Wi-Fi and c) Cellular 
phone network : 
• Bluetooth serves for communication with the wearable device.   
• Wi-Fi serves as communication channel with the Cloud. It will utilize the local Wi -Fi network and 
router. Wi -Fi is the Default channel.  
• Cellular phone network –  serves as backup communication channel in case the Wi -Fi is either not 
available or does not function properly.  
This dedicated mobile application enables easy usage by [CONTACT_215670] l as full control of the device . The 
application will also be in charge of the protection of the data when it is sent from the sensors over Bluetooth 
(BT) and when it is sent to the cloud computing module (CCM) via TCP/IP. Full compliance with medical data 
security will be employed.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 22 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
There are two mobile applications used with PregSense™ : PregSense MD and PregSense ME. Additio nally, 
there is a dedicated App for this Pi[INVESTIGATOR_2397], which was developed in order to show an agreement between 
the standard of care monitoring system (i.e. CTG) and PregSense , as described below:   
 
3.5.1 MD App lication :  
This application is used by [CONTACT_215671] a mobile device (smartphone/tablet) or stationary device 
(PC)  in order to monitor the pregnant patient . The MD App will present the following parameters:  
• FHR – figures presented as beat/min + graph (of the entire session) MHR - figures presented as 
beat/min + graph (of the entire session)  
• Uterine Activity (Uterine Contractions, if applicable)  
• Customized/ personal setting – Alerts  (to be managed by [CONTACT_099])  
• Ranges reference (according to ACOG)  
• Telemedicine  
3.5.2 ME App lication :  
This application is used by [CONTACT_215672] a  mobile device (smartphone/tablet) .  
PregSens e™ Mom App presents the following parameters :  
• FHR average (per min) + Ripples9 
• MHR average (per min) + Ripples  
• Fetal Heart Rate response (presented as Fetal activity10)  
• Maternal Activity  
• Uterine Contractions (if applicable)  
• Telemedicine  
Telemedicine: the pregnant women and her assigned doctor/medical supervisor can share the monitored data 
and communicate via telemedicine and can:  
• Enable access to session's data from remote location  
• Perform audio/video chat option 
For this Pi[INVESTIGATOR_108516], and in order to assess the agreement between PregSenseTM data collection, and values 
measured via the standard of care used for prenatal monitoring (i.e. CTG) and to assess the safety of 
PregSense ™ (as per study endpoints). A dedicated study App will be applied wi th the following parameters:   
• Synchronous log of PregSense and the CTG, recording data to the cloud (for agreement 
purposes between both devices)    
• Subject demographic details screen (in accordance with GCP guidelines)  
• Real time events insertion (for safety evaluation)  
• Graph summary per session (CTG like)     
 
                                                      
9 “Ripples ” - a graphic presentation of the heartbeat,  excluding any figures or any quantitative information.  
10 A derivative of FHR analysis  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 23 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
3.6 Device  safety  - Compliance Pre -clinical 
3.6.1 Compliance and Pre -Clinical  
The pre -clinical testing that was performed on PregSense is described hereunder:  
(1) Electrical Safety testing :  
• EN [ZIP_CODE]- 1:2006/A1:2013 [EU harmonized version] & ANSI/AAMI ES60601-
1:2005/(R) 2012 and A1:2012, C1:2009/(R) 2012 and A2:2010/(R) 2012 [FDA 
recognized version] Medical electrical equipment - General requirements for basic 
safety and essential performance.  
• IEC [ZIP_CODE]- 1-11: 2010 / IEC [ZIP_CODE]- 1-11: [ADDRESS_259447]: 
Requirements for medical electrical equipment and medical electrical systems used in 
the home healthcare environment  
(2) EMC:  
• EN [ZIP_CODE]- 1-2: 2007 [EU harmonized version] & IEC [ZIP_CODE]- 1-2: 2007 [FDA 
recognized version] Medical electrical equipment -  General requirements for basic 
safety and essential performance – Collateral standard: Electromagnetic compatibility 
- Requirements and tests (FDA also recognizes the 4th edition of this standard, IEC 
[ZIP_CODE]- 1-2: 2014. 
• FCC CFR 47  
(3) Bioc ompatibility testing : 
Nuvo PregSense sensors are produced under ISO [ZIP_CODE] quality system. The sensors were tested 
for biocompatibility according to ISO [ZIP_CODE] -1, ISO [ZIP_CODE]- 5 for:  
• In-vitro cytotoxicity  
(4) Batteries:  
• UL 1642 5th edition for Lithium Batteries .  
• IEC [ZIP_CODE]: 2012 Secondary Cells a nd Batteries Containing Alkaline o r Other Non -
Acid Electrolytes - Safety Requirements For Portable Sealed Secondary Cells, And For 
Batteries Made From Them, For Use In Portable Applications.  
(5) Tests performed by N uvo Group:  
• Each Software version of the system is verified according to the Software standards 
ISO [ZIP_CODE]- 1 section 14 and ISO [ZIP_CODE]. 
• FDA Guidance document –  General principles of software Validation: Final Guidance 
for Industry and FDA Staff.  
• Each system undergoes strict functionality testing before release according to written 
test procedures.  
 
3.6.2 Previous C linical  evaluation  
A study evaluating the Fetal He art Rate  (FHR)  data recording for developi[INVESTIGATOR_007]  a continuou s FHR  
monitoring using a designated sensory belt  was conducted in Hadassah Hospi[INVESTIGATOR_307], Jerusalem, Israel . 
This study was conducted to assess the feasibility and safety  of PregSense™ .  
During the feasibility  study a total of [ADDRESS_259448] s aged ≥ 18 years and ≤ 50 years  with singleton pregnancy 
between 20- 40 weeks’  gestation and  who were  capable of signing  informed consent were included 
in the study.  
PregSense ™ was recorded simultaneously wi th the industry standard BIOPAC ™ MP-150 bio-
medical data acquisition system. No adverse events, procedure- related or device- related , were 
reported during the study.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259449] ISO  
[ZIP_CODE]:2012 / ISO [ZIP_CODE]:2007 Medical devices -  Application of risk  management to medical devices.  
• All risk control measures have been implemented and verified. The overall residual risk for the device 
has been found to be acceptable using the criteria defined in the risk management plan.  
• A review of the individual risks against the benefits of the device indicates that the benefits of the device outweigh the risks involved in all cases.  
For further risk analysis information, please see the section 11.2 in the Investigator Brochure  
4 STUDY ENPOINTS  
4.1 Primary Performance Endpoints : 
The primary performance endpoints will include:  
• Fetal HR  
Maternal HR Both  endpoints will be collected via PregSense™ and via the standard of care monitoring system 
(CTG).  
4.2 Safety endpoints:  
Incidence of device related and/or protocol procedure related adverse events and/ or serious adverse events related to the study device, in pregnant women with singleton pregnancy > 24 + 0 weeks of 
gestation.  
4.3 Secondary Performance  Endpoints:  
The secondary performance endpoints will include:  
• Uterine contractions  
 
PregSense™ also acquires and displays the UA (Uterine contractions) tracing from the uterine 
Electrohysterography (EHG) signal.   
Contractions will be  collected via PregSense™ and via the standard of care monitoring system (CTG).  
[ADDRESS_259450]  data from PregSense ™, and the standard of 
care ( CTG)  in order to provide evidence of safety and agreement between PregSense ™ and the  standard 
of care devices (for further information see section 6.1.2, and 8.2) . 
During the study conduct , Nuvo Group will continuously review adverse events and will meet (as n eeded) 
periodically to review the accumulated safety data (for further information, see section 9) . 
5.1.[ADDRESS_259451]  number and will sign an 
Informed Consent Form (ICF) prior to any study procedure initiation. Each subject will receive a 
detailed explanation about the study  purpose and procedure; at the end of the explanation, the 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259452]'s measurements and 
vital signs and will confirm that the subject meets the Inclusion/ Exclusion criteria.   
Sites will make all efforts to maintain a  balanced distribution of subjects across the different weeks 
of pregnancy . An attempt will be made to include at least  5 women with contractions in each site. 
 
5.1.2 Recording session  
The primary objective is to assess the agreement between the PregSense ™ device data collection, 
and the values as measured via the standard of care used for prenatal monitoring (i.e. CTG).  
First, the authorized study personnel  will register the subject into the A pp. If the subject is already 
registered, the subject's study I.D number will be entered to the A pp.  
PregSense ™ WSB  then will be applied  by [CONTACT_215673] a damp cloth , then drying 
the abdomen. Before initiating the recording session, a valid signal should be obtained. Therefore, 
a [ADDRESS_259453] ment of  the 
PregSense ™ WSB connections and placement  should be re-validated , then another validation test 
will follow (i f validation test does not pass after three adjustments the subject shall be excluded).  
Once the validation test has passed, a [ADDRESS_259454] of care procedure . 
If a valid  signal  is detected , a new  30-minute  session will be initiated recording  both systems 
simultaneously  in a synchronize d method (PregSense ™ and CTG) .   
Following the completion of the  sessions , the nurse/clinician will remove both monitoring systems 
from the maternal abdomen .  
5.[ADDRESS_259455] may withdraw or be withdrawn from the study for the following reasons:  
• Subject withdrew consent.  
• Request of Sponsor to terminate the study.  
• Request of primary care physician or investigator.  
• Subject is non -compliant with study procedures.  
• Protocol violation.  
• Subject is unable to continue the study.  
• Subject experiences an adverse event (whether considered relat ed to the investigational product 
or not) that results in a medical condition that may prevent the subject from meeting study 
criteria.  
• Death.  
Reasons for premature withdrawal from the study must be stated in the CRF and in the site source 
documentation.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 26 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
If there is  more than one reason for early withdrawal from the study, all the reports  should be stated.   
The study may be stopped following an unexpected event, which does not permit continuation of 
the study. The Investigator and/or the Sponsor and/or local EC  and/or regulatory 
authority/Competent Authorities can decide to terminate the study .  
The data collected up until the withdrawal point will be valid and available for insertion in to the 
study database and the development of the analysis.  
5.2.2 Sponsor’s Termination of Study  
The Sponsor reserves the right to discontinue the study at any time for any reason.  The Spons or 
may also discontinue the study at a site due to poor  performance or compliance.  The investigator 
must implement the Sponsor's request to terminate the study in a time frame that fits best with the 
subjects’ well -being. 
 
[ADDRESS_259456] ELIGIBILITY  
6.1 Inclusion criteria:  
The study population will consist of the following inclusion criteria:  
1. Female age  between : 18-50 
2. Gestational age > 32 + 0  weeks   
3. Singleton pregnancy  
4. Ability to understand and sign informed consent  
6.2 Exclusion criteria  
1. BMI ≥45 and 15≤ prior pregnancy 
2. Multiple gestation  
3. Fetal Anomaly  
4. Uncontrolled Hypertension  
5. Subjects with skin problems in the abdominal area (such as; wounds, cuts in the skin, skin 
rash, etc.)  
6. Subjects with implanted electronic devices (pacemakers, defibrillator, etc.)  
7. Subjects who, in the judgment of the investigator, are likely to be non -compliant or 
uncooperative during the study 
[ADDRESS_259457]  
7.1 Screening  & Enrollment  
The enrollment procedure will include:  
• Assessment of eligibility to participate in the study . 
• Informed Consent must be obtained prior to enrollment . 
• The subject will undergo routine registration procedure and will be identified by a personal code in 
addition to their initials . 
• The Case Report Form (CRF) will be filled  by [CONTACT_215674]/or authorized 
personnel , including recording of all relevant subject details (such as Weight, height, estimated Due 
date, concomitant medications, medical history, date of signature [CONTACT_106253], recording date and hour, 
problems detected during recordings, etc.) . 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 27 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
7.1.1 Assessment of eligibility  
Study authorized personnel will evaluate subjects’ eligibility to participate in the study.  All 
potential trial candidates will be s creened for eligibility. Only subjects who meet all inclusion 
criteria and none of the exclusion criteria will be eligible for enrollment.  
Eligibility to participate in the study will be ascertained by [CONTACT_215675].  
Sites will make all efforts to enroll an equal number of the subjects across the different  gestational 
age.  
7.1.[ADDRESS_259458] ; a signed copy will be given to the subject .  
A subject  identification log (LOG -CLI-04-04) will be kept at the site with a ll subjects signed ICF 
documentation for participating in the study . The log will include the subject ’s full name , ID 
number, initials, subject number and date of enrol lment.  
7.1.[ADDRESS_259459] digit will be the code of the country; “1” for [LOCATION_013], “2” for [LOCATION_003] etc.  
The 2nd and 3th digits will be the code of the site; “01” for Heidelberg, “02” for Hadassah etc. the 
5th, 6th and 7th digits will be the code of the protocol; “100 0” for the Pi[INVESTIGATOR_215642]. The last 3 
digits ( 8th to 10th digits) will be the code of the subject  CRF number; “001, “002” etc.  
The identity of all study participants will be kept strictly confidential.  
7.[ADDRESS_259460] of 
care.   
Important Note: The physician or any other medical personnel are not allowed to make any 
medical decisions or treatments based on the information received from PregSense ™.  
7.2.1 Recording  
The PregSense ™ will be connected and operated in the most continuous manner as possible  
recording the fetal cardiac activities and maternal cardiac activities, unless there is a necessity to 
disconnect the subject  due to medical treatment or nursing reasons.   
The data will include the following: 
• Fetal HR  
• Maternal HR  
• Uterine activity  
The Preg Sense™  records will be identified by [CONTACT_423] 's trial identification number.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 28 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
7.2.2 CTG and data recording  
The data from the CTG  + Pulse Oximeter monitoring system  will be recorded in real time by a 
dedicated SW system  in parallel to the PregSense™ .  
A pulse Oximeter is used to monitor MHR with the CTG/NST device.  
All data should be stored under the subject study ID number  and will be analyzed offline.  
7.2.3 Testing Set -up 
Additional equipment to be used during the testing:  
• CTG - Phillips Avalon FM30 /FM20  + Pulse Oximeter with  a dedicated  PC and cable 
connections    
• Ultra Sound Imaging if applicable  
7.[ADDRESS_259461] of Care in accordance to the general 
management  of the site.  
7.4 Concomitant tests, therapy and treatment  
All concomitant medications/therapi[INVESTIGATOR_215643]. There are no restrictions on the use of concomitant 
medications, as dictated by [CONTACT_19911].  
Any investigational medication/therapy or off -label uses of drugs and devices are prohibited during the 
study. 
7.5 End of study/ Completion of study  
Completion of study will be defined by [CONTACT_215676],  thus, subjects who finished the study 
without protocol violations and had at least 1 minute of data where a signal was recorded and detected  
with both devices at the same time.  
8 ASSESSMENT OF SAFETY  
PregSense ™ is a passive “listening” tool  - there is no energy transmitted into the body (unlike ultrasound 
and Doppler). The sensor communicates with the smartphone /tablet  via Bluetooth. Bluetooth is a standard 
very common,  low-energy communication technology. 
8.[ADDRESS_259462] be carefully monitored for adverse events. Adverse events should be assessed in terms of 
their seriousness, intensity, duration, resolution status and relatedness to PregSense ™ usage . The 
outcome of each adverse event must be observed and documented.  
8.2 Adverse events  
There are no known adverse events related to the use of PregSense ™, however, there are possible 
adverse events related to monitoring  systems which involve  sensor applicati on on the skin . These 
include the following:  
• Edema  
• Erythema  
• Irritation  
• Sensitization  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 29 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
An adverse event is any undesirable experience (sign, symptom, illness, abnormal laboratory value, or 
other medical event) occurring to a subject , user or a third person, that appears or worsens during a 
clinical trial. An adverse event may or may not be r elated to the investigational device prescribed as 
part of the trial protocol.  
 
8.2.1 Severity  definition : 
• Mild: AE which is easily tolerated  
• Moderate: AE sufficiently discomforting to interfere with daily activity  
• Severe: AE which prevents normal daily activities  
The Primary I nvestigator (PI) will document in his opi[INVESTIGATOR_215644] (medical device) using the criteria outlined below:  
8.2.2 Relationship  of an adverse event to the Treatment/ Device  
• Unrelated : The AE has no temporal relationship to study device, and/or there is evidence of 
alternative cause such as concurrent medication or illness.  
• Possibly related : A temporal relationship with study device is not clear, alternative causes are 
also possible . 
• Probabl y related : A clear cut temporal relationship to the use of study device and potential 
alternative etiology is not apparent . 
• Definitely related : A clear cut temporal relationship to the use of study device and no other 
possible cause.  
8.3 Adverse Events (AE) and Severe Adverse Events (SAE) Reporting  
The following shall apply to events occurring throughout the trial:  
All severe adverse events (SAE) must be reported to the Sponsor within 24 hours after the investigator 
learns of the event, by [CONTACT_29658] /e-mailing  the completed Adverse Event Form . 
The contact [CONTACT_215677]:  
Nuvo Group Ltd.  
11th Menachem Begin Rd.  
Ramat Gan, Israel  
Fax: +972- 3-5294072 
Email: adar.shani@nuvo -group.com  
 
The sponsor is required to submit a full SAE report as applicable per regulations in each country. A full 
investigation and report must be submitted by  [CONTACT_215678], 
and/or to all reviewing IRBs /EC as soon as possib le, but no later than [ADDRESS_259463] submit 
any additional reports concerning the event, as FDA /MOH  requests.  
All other events, including technical  failures, will be reported to the Sponsor every monitoring visit, 
confirmed in writing by [CONTACT_978]  [INVESTIGATOR_215645] , user or a third person  in the trial must be evaluated and 
documented in the CRF and will be reviewed by  [CONTACT_215679], as 
applicable, reported to the Institutional Review Board (IRB) and other appropriate parties  per country 
regulations . 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259464]. The purpose of this study is to demonstrate safety and performance of PregSense.  
9.2 Study Endpoint Measures  
9.2.1 Primary Performance Measures  
Fetal heart rate (FHR) as measured by [CONTACT_215680] ™ versus the standard of care (i.e. CTG ). 
Maternal heart rate (MHR) as measured by [CONTACT_215680] ™ versus the standard of care (i.e. CTG ). 
Both parameters are measured continuously for a duration of 30 minutes with data sampling taken at 1-
minute intervals in parallel with both study devices.  
9.2.2 Safety Endpoint Measures  
Incidence  of device related and/or protocol procedure related adverse events and/or serious adverse events 
related to the study device, PregSense ™, in pregnant women with a singleton pregnancy > 24 +0 
gestational weeks.  
9.2.3 Secondary Performance Measures  
Uterine contra ctions  as measured by [CONTACT_215680] ™ versus the standard of care (i.e. CTG including TOCO  
recordings ). 
The parameters are measured continuously for a duration of 30 minutes with data sampling taken at 1 -
minute intervals in parallel with both study devices.  
Three  blinded assessors  will review the recordings and determine for each time point whether a 
contraction occurred.  
9.3 Success Criterion  
The study will be deemed successful if the limits of agreement (LOA’s)  for FHR and MHR between 
PregSense and the standard of care device are within  the interval [-7, 7] Bpm.  
In the literature, the limits of agreement for both FHR and MHR with FSE, abdominal fetal ECG and 
ultrasound were clinically evaluated showing that the abdominal fetal ECG limits of agreement is (± 
1.96 SD) 8.40; −8.7211. 
9.4 Sample Size Justification  
The company intends to recruit a minimum of 50 subjects for this study. An attempt will be made to 
include 5 subjects with contractions per site.  
The minimum recommended number of measurements for a method comparison study as per EP09-
A3: “Measurement Pro cedure Comparison Bias Estimation Using Patient Samples Approved 
Guideline – Third Edition”) is a sample size of 40 laboratory samples (subjects in our case). The 
devices will record for [ADDRESS_259465] 50 subjects are recruited for 
the study there will be up to 1000 measurements of heart rate with both devices and no less than 250 . 
                                                      
11 http://beijingyes.com/download/Holter_2_Accuracy_and_reliability_of_fetal_heart_rate_monitoring.pdf  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 31 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
In addition, from preliminary company data the mean difference between FHR measurements with two 
methods  was 0.695BPM (SD= 1.15BPM), using the sample size equation from Lu MJ, Zhong WH, 
Liu YX, Miao HZ, Li YC, Ji MH (2016) Sample size for assessing agreement between two methods 
of measurement by [CONTACT_115525] -Altman method. The International Journal of Biostatistics  12: issue 2 (pp. 
8), we find that with a sample size of at least 50 subjects the acceptance criterion can be met at a 5% 
level of significance and with 90% power even if the standard deviation is almost twice as high as 
seen in the feasibility  study. 
An a cceptable outcome for the secondary performance measure of Uterine contractions agreement is 
85%, in order to estimate this parameter with a two -sided 95% exact binomial confidence interval 
having a half -width  of ±10% at least [ADDRESS_259466] correlation is moderate (r=0.5) then a sample size of 44 women will be sufficient to measure this endpoint with acceptable reliability.   
9.5 Data Analysis Sets  
Full Analysis Set / Safety Analysis Set  (SA) 
The safety analysis (SA) set includes all subjects who were enrolled and underwent study procedures 
in with data available for analysis.  
9.5.1 Performance  Analysis Set  (PA) 
Because each monitoring modality sometimes fails to generate cli nically interpretable data, rules were 
applied to facilitate statistical analysis.  
The performance analysis set will consist of all subjects who finished the study without major protocol 
violations and had at least 1 minute of data where a signal was recorded and detected   with both devices 
at the same time. Possible reasons for exclusi on of a data point from this analysis set may include but are 
not limited to the following:  
Invalid signal in one of the systems, i.e PregSense™  and the CTG system due to:  
1. Device malfunction  
2. Maternal movement  
3. Device positioning does not enable signal recording  
4. Interaction between devices  
9.5.2 Statistical Analysis of Analysis Sets  
The SA set will serve as the analysis set safety assessments. The performance assessments will be 
performed on the PA  set. 
9.6 Statistical Analysis  
9.6.1 General Considerations  
Statistical analyses will be performed using SAS® v9.4 or higher (SAS Institute, Cary NC, [LOCATION_003]). 
Statistical analyses and reporting will be performed in compliance with FDA Guidance E6 GCP and E9 
and ISO [ZIP_CODE]. 
Baseline demographic together with safety analyses will be performed on all subjects if the SA set. 
Baseline values are defined as the l ast valid value prior to study device use.  
If statistical tests are performed, nominal p -values will be presented. All statistical tests will be two -sided.  
Where confidence limits are appropriate, a two -sided 95 % confidence interval will be constructed.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 32 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
For comparison of means (continuous variables), the two- sample t -test or the Wilcoxon rank sum test will 
be used as appropriate.  For comparison of proportions (categorical variables), the Chi -squared test or 
Fisher’s exact test will be used as appropriate.  
If multiple measurements are taken in a single subject, statistics will be appropriately modified to 
accommodate the within subject correlation.  
9.6.[ADDRESS_259467] disposition will be tabulated; the number  of enrolled, exposed to study device, prematurely 
terminated and completed as planned subjects will be summarized, including the number of subjects in each analysis population. Device tolerability and compliance will be presented, the number and percent 
of subjects who fail to complete the study and the number and percent of subjects who fail to complete 
the study because of adverse events will be presented . A list of discontinued subjects, protocol deviations, 
and subjects excluded from the performance analyses will  also be provided.  
9.6.4 Performance analysis 
[IP_ADDRESS]  Primary performance : 
Fetal heart rate (FHR) and maternal  heart rate (MHR) will both be analyzed in a similar manner as 
follows :  
A comparison between PregSense™  measurement of FHR and MHR versus the  reference measurements 
(i.e. CTG) are made using methods described by [CONTACT_148807]12.  
The correlation (Pearson’s correlation coefficient) and mean difference between the reference and PregSense ™ measures of FHR and MHR will be presented together with a 95 % confidence interval. A 
high correlation and a mean difference value near zero are expected if the two devices (Reference vs. 
PregSense ™) output the same values.  
In addition, a Bland- Altman plot of the mean versus the difference will be presented, and the 9 5% limits 
of agreement calculated together with respective confidence intervals. As a measure of accuracy, the 
mean bias and its standard deviation (with 95% con fidence intervals) are estimated from random effects 
analysis of variance models programmed in SAS® using the MIXED procedure. This is done to 
accommodate the within subject correlation due to repeated FHR and MHR measurements.  
Linear regression models (Deming or Passing -Bablok regression as appropriate) will be fitted to the 
values obtained from both devices of FHR and MHR ; the slope and intercept together with respective 
95% CI ‘s will be presented.  The confidence interval s of the regression parameters will be calculated with 
bootstrap methodology using 10,000 simulated samples  as well.  
[IP_ADDRESS]  Secondary performance:  
Uterine contractions as measured by [CONTACT_215680]™ and the standard of care (i.e. CTG including TOCO recordings), are measured continuously for a duration of 30 minutes with data sampling taken at 1- minute 
intervals in parallel with both study devices. We shal l count the number of contractions (may be more 
than one per subject) as determined by [CONTACT_215681]™ and the standard of care. The percent of agreement (i.e. positive agreement) will be presented , the denominator of this fraction will be the standard of care  number of 
identified contractions per subject . The binary positive agreement variable will be modeled with a 
                                                      
12   https://en.wikipedia.org/wiki/Bland%E2%80%93Altman_plot 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 33 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
repeated measures model for binary data using the GENMOD procedure in SAS (link=identity dist=bin). 
This is done to accommodate the within subject correlation due to repeated measurements. The int ercept 
of the model is the parameter of interest; this will be presented with corresponding 95% confidence 
interval. A point estimate for the agreement that is considered acceptable is 85%.  Note that if the 
agreement will be 100% a Wilson score confidence interval will be presented instead.  
The false positive alert rate will be analyzed  in a similar manner. At each time point, n o notation of a 
contraction by [CONTACT_215682], therefore the 
false posi tive alert rate will count the number of fals ely identified contractions  by [CONTACT_215683]™  
relative to the SOC.  
[IP_ADDRESS]  Safety  Analysis  
Adverse events (AE) will be presented by [CONTACT_12917], severity  and relation to study device. The primary 
safety variable, the cumulative incidence (and 95 % CI) of device -related adverse events (AEs) and SAE’s 
observed throughout the follow -up period, will be presented in a tabular format. A detailed list of all 
adverse events will be presented. The adverse event rate will be compi[INVESTIGATOR_215646], nature, severity of the event, and relationship to the study device. In addition, listings of all safety 
measures will be provided.  
The rate of SAE's, if any, associated with use of P regSense ™ is expected to be very small.  
9.6.[ADDRESS_259468] one 
data point to the analysis of the primary endpoint, therefore only missing  data points will be excluded 
from the analysis of the relevant endpoint.  
 
10 STUDY MONITORING & QUALITY ASSU RANCE AUDITS / INSPECTIONS   
10.1 Good Clinical Practice  
The study described in this protocol will be carried out according to the local regulatory requirements 
(FDA, EU) and ICH accepted standards of Good Clinical Practice. All procedures not described in this 
protocol will be performed according to the approve d written Standard Operating Procedures unless 
otherwise stated.  
10.2 Monitoring Procedures  
The Study Monitor will be responsible for ensuring adherence to FDA, EU Directives, ICH guidelines and the Sponsor’s Standard Operating Procedures.  
Experienced independent monitors or monitors from CROs/Sponsor will be trained in the Sponsor’s SOPs, study  protocol and the study monitoring conventions.  
Regular monitoring of study data at each site will be performed as defined by [CONTACT_215684].  Individual sites will be monitored to verify that enrollment rate, data recording, and 
proto col adherence are satisfactory. The frequency of monitoring individual sites may fluctuate 
depending upon enrollment rate, quantity of data collected and the complexity of the study and will be 
described in the monitoring plan.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 34 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
These monitoring visits will be performed for the purposes of verifying adherence to the protocol and 
the completeness and accuracy of data entered on the CRF.  The study monitor will verify CRF entries 
by [CONTACT_215685] (hospi[INVESTIGATOR_307]/clinic/office recor ds), which will be 
made available for this purpose.  The monitor will review the maintenance of regulatory documentation 
and device accountability.  The monitor will review the progress of the study with the investigator and 
other site personnel on a regul ar basis.  At the end of the study, a close- out monitoring visit will be 
performed.  Monitoring visits will be arranged in advance with site personnel at a mutually acceptable 
time.  Sufficient time must be allowed by [CONTACT_215686]. The coordinator and/or investigator should be available to answer questions or 
resolve data clarifications.  
10.3 Quality Assurance Program  
This clinical trial may be audited according to the Nuvo Group  Quality Assurance (QA) program/ Nuvo -
Group designee.  
The purpose of these audits is to determine whether the study is being conducted and monitored in 
compliance with the protocol as well as recognized GCP guidelines and regulat ions. These audits will 
also increase the li kelihood that the study data and all other study documentation can withstand a 
subsequent inspection by [CONTACT_215687].  Such audits, if necessary, will be pre -arranged with 
the site and conducted within a reasonable time frame.  
10.[ADDRESS_259469] at any time during or after the study and are based on the national regulations, as well as ICH guidelines.  
 
11 USE OF INFORMATION AND PUBLICATION 
11.1 Confidential Information  
All information supplied by [CONTACT_215688], is considered confidential information. This information includes, but is not limited 
to, the Investigators' Br ochure, clinical protocol, case report forms and other scientific data. Any data 
collected during the study are also considered confidential. This confidential information shall remain 
the sole property of Nuvo  Group, shall not be disclosed to others without the written consent of Nuvo 
Group, and shall not be used except in the performance of this study. 
The information developed during the conduct of this clinical study is also considered confidential and 
will be used by [CONTACT_215689]. The information may be 
disclosed as deemed necessary by [CONTACT_215690]. To allow the use of the information derived from this 
clinical study, the investigator is obliged to provide Nuvo  Group with complete test results and all data 
developed in this study. The information obtained during this study may be made available to other 
investigators who are conducting similar studies.  
Should the investigator wish to publish the results of this study, the investigator agrees to act according 
to Nuvo  Group Publication policy. 
 
[ADDRESS_259470] of clinical trials, as applicable by [CONTACT_215691] -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 35 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
legislation and EU Directives, including 93/42/EEC, 90/385/ EEC, ISO 14155and US 21 CFR Part 812 
and local regulations where applicable.  
12.2 Informed Consent  
The principles of Informed Consent, according to Declaration of Helsinki 1964 and all its updates, ICH 
guidelines on GCP, 21 CFR part 50 of the FDA Regulations and/or EU Medical Devices Directives 
93/42/EEC, 90/385/EEC and ISO [ZIP_CODE], will be followed. A subject should not enter a clinical study 
until he/she has been properly informed, has been given time to contemplate participation, and has freely 
given his/her consent by [CONTACT_215692]/IRB approved informed consent form.  This must 
be done prior to performing any study related procedures.  
The proposed consent form and any other documents relevant to the consent process, must be submitted 
to the Ethics C ommittee/Institutional Review Board (EC/IRB), together with the protocol, and must be 
approved prior to study start.  
A copy of the fully signed and dated Informed Consent and any other documents relevant to the consent 
process will be given to the subject and the original will be maintained at the site.  
12.3 Ethics Committee (EC) / Institutional Review Board (IRB)  
The study must have unconditional approval in writing, by [CONTACT_137891]/Institutional Review Board (EC/IRB). A copy of the Letter of  Approval from the EC/IRB, 
which contains specific identification of the documents approved, must be received by [CONTACT_215693].  
Any amendments to the protocol or subsequent changes to the informed consent form as a result of changes t o the protocol and/or investigator brochure that is approved by [CONTACT_215690], must also be 
approved, as appropriate, by [CONTACT_1383]/IRB and documentation of this approval provided to Nuvo  Group. 
Records of the EC/IRB review and approval of all documents pertaining to this study must be kept on file by [CONTACT_215694]/or sponsor inspection during or after 
completion of the study.  
Serious/ unanticipated adverse events (SAEs) must also be reported to the EC/IRB by [CONTACT_215695].  
Periodic status reports must be submitted to the EC/IRB as required, as well as notification of 
completion of the study and a final report where applicable. A copy of all reports submitted to the 
EC/IRB must be sent to the sponsor . 
12.[ADDRESS_259471] be approved by [CONTACT_215696]’s EC/IRB prior to 
implementation.  
12.[ADDRESS_259472]’s consent, the investigator will permit the study monitor, independent auditor or 
regulatory agency personnel to review that portion of the subject’s medical record that is directly related 
to the study.  This shall include all study relevant documentation including subject medical history to 
verify eligibility, laboratory test result reports, admission/discharge summaries for hospi[INVESTIGATOR_215647], and autopsy reports for deaths occurring during the study (where 
available).  
Subject authorization must allow Nuvo  Group to receive and review the subject’s protected health 
information which may be re -disclosed to any authorized representative of Nuvo  Group, Central 
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259473] be received by [CONTACT_215697]:  
• Confidential Non -Disclosure Agreement  
• Signed protocol, amendments and notifications pages  
• The Principal Investigator’s curriculum vitae and where required current medical license  
• Signed Clinical Study Agreement and Signed Investigator Agreement  
• EC/IRB written approval for the Protocol, Amendments, Informed Consent , Subject  Information 
Sheet  
• EC/IRB Membership list or an official statement from the EC/ IRB stating the they are  in compliance 
with 21 CFR part 56  
• Financial disclosure information  on possible conflicts  from all  investigator s  
 
13.2 Study Documentation Supplied by [CONTACT_215698]/ CRO will supply the investigator with the following items:  
• Case Report Forms (CRF)  
• Regulatory Binder  
• Template Informed Consent  
• Valid Insurance Certificate  
• Operations Manual  
13.[ADDRESS_259474] maintain primary source documents to support CRF data entries. These 
documents, which are considered “source data”, may include but are not limited to:  
• Demographic information  
• Ultrasound results (if applicable)   
• Evidence supporting the  diagnosis/condition for which the subject is being studied 
• General information supporting the subject’s participation in the study  
• Medical history and physical findings  
• Hospi[INVESTIGATOR_94585] (if applicable)  
• Any relevant findings/notes by [CONTACT_093](s), occurrence (or lack) of adverse events, and 
changes in medication usage, including the date the study medication was commenced and 
completed  
• Original, signed informed consent forms for study participation  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259475] specific printouts/reports of tests/procedures performed as 
a requirement of the study. During monitoring visits , the monitor will need to verify data in the CRFs 
against these source data.  
13.4 Additional Documents and Records  
• Subject Screening and Assignment Log  – A listing of all subjects who signed the informed consent 
and were screened.  
• Subject Identification Record  - This allows linking of the enrolled subject to the study. Information 
should include, but is not limited to : subjects’ name, date of birth and contact [CONTACT_3031]. This 
confidential list will be maintained by [CONTACT_215699].  
• Device Inventory/Shipment Form  – This form documents the total amount of devices shi pped to the 
site and received and acknowledged by [CONTACT_093], or designee.  
• Device Accountability Log  – This form documents the total amount of study device dispensed to 
and returned by [CONTACT_6992].  
13.5 Maintenance and Retention of Records  
It is the responsibility of the investigator to maintain a comprehensive and centralized filing system of 
all relevant documentation  in accordance to the local ethical standards.  Investigators will be instructed 
to retain all study records required by [CONTACT_215700] a secure and safe facility 
with limited access for one of the following time periods based on notification from Nuvo  Group:  
• A period of at least two years from last marketing authorization and notification from sponsor  
• A period of at least two years after discontinuation of clinical development of the investigational 
product as confirmed by [CONTACT_215690] 
• Longer , if required by [CONTACT_215701], disposition, or custody of 
the study files.  
 
[ADDRESS_259476]  
All investigational devices will be provided to the clinical sites by [CONTACT_215690], and Nuvo  Group will 
be responsible for device servicing and replacement.  All failures and malfunctions will be reported to Nuvo  Group within 24 hours  via e -mail to: A dar.sha ni@nuvo -group.com . 
14.1 Supply and Disposition of Study Devices  
An adequate number of PregSense™  will be supplied to the study sites before initiating the study.  
Upon completion of trial, the device s will be returned to the Sponsor to avoid unauthorized use.  
Each shipment of device supplies for the study will contain a shipment form to assist in maintaining 
current and accurate inventory records. When a shipment is received, the investigator/coordinator will 
acknowledge receipt.  
14.[ADDRESS_259477], the date, lot number, expi[INVESTIGATOR_215648], and the date and quantity of devices 
returned will be recorded. The devices wi ll be noted on the appropriate inventory forms.  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. [ADDRESS_259478] be returned to the sponsor or sponsor’s designee. Ancillary 
supplies may not have to be returned.  
Upon Nuvo  Group/ Nuvo  Group designee visit at the site, accountability o f the returned devices should 
be performed and recorded.  
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 39 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
15 APPENDICES  
15.1 Appendix 1 –Recording Session Flow  
Figure 8 Recording Session Flow  
Apply
Wearable  Sensory 
Belt 
1-3 
Minutes 
Recording  
Apply CTG Transducers 
and Confirm Fetal 
Heart-Rate Detection  Recording session Flow
Pass Fail
Adjustment (up to 3 times)
Pass Fail
Remove PregSense 
Wearable Sensory Belt, CTG 
Transducers 
Adjustment (up to 3 times)Start New 
Session in AppApp 
Registration/ 
Sign In
Record 10 
Minutes 
Start New Session in App 
Simultaneously recording the 
PregSense and CTG for 30 
minutes
Stop session in 
AppI[INVESTIGATOR_215649] -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 40 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
 
15.2 Appendix 2 – Pi[INVESTIGATOR_215650] 9 Pi[INVESTIGATOR_215651]
(subject already had ID)
On Boarding 
Parameters 
(Fixed parameters)
Add Session 
Parameters Trial Parameters 
Generate Subject ID 
“Start” Session  
Session Summary 
Subject ID ValidationRegistration 
SessionClinician/Nurse Login
Upload File
(Off line mode session)Clinician/Nurse Logout
Change Patient
Off Line Mode
Upload File when 
internet connection is 
available
(Off line mode session) 
  
 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 41 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
15.3 Appendix 3 – Pi[INVESTIGATOR_215652] 10 Pi[INVESTIGATOR_215634]:  
 
 
 
 
 
 
  
 
 
 
 
  
 
 
  
Adding patient 
details and real time  
annotations/events  
BT 
 Internet  
CTG graphs  
Grid paper print  
CTG cable 
connection 
to Tablet   
Internet  
 Internet  
Grid paper  
printer  
PregSense graph 
presentation  

 
  
CLINICAL STUDY EVALU ATING THE SAFETY OF THE NON -INVASIVE 
PREGSENSE™ AND COMPARATIVE PERF ORMANCE OF PREGSENSE ™ 
VERSUS CTG INPRENATAL MONITORING OF PREGNANT SUBJECTS  
Ref. No.: CLP1000  Rev. 05 Page 42 of 42 
 
Confidential and proprietary - distribution or any commercial or other external use of this document is forbidden  
16 REFERENCES  
(1) Bowers, Nancy A., Sara Foster , and Louise Akin. "External  and Internal Heart Rate Monitoring of  
Fetus."  University of [COMPANY_002]ster Medical Center. [COMPANY_002]ster: 2016. Web.  
(2) Coles, Mandy S., May Lau, and Aletha Y. Akers. "If You Do Not Ask, They Will Not Tell:  
Evaluating Pregnancy Risk in Young Women in Pediatric Hospi[INVESTIGATOR_600]."  Journal of Adolescent  
Health  58.3 (2016): 251- 52. Web.  
(3) Elixhauser, Anne, Ph.D, and Lauren M. Wier, M.P.H. "Complicating Conditions of Pregnancy and  
Childbirth, 2008."  Healthcare Cost and Utilization Project  (2011): n. pag. Agency f or  
Healthcare Research and Quality, May 2011. Web.  
(4) "Fetal Heart Monitoring." Johns Hopkins Medicine, n.d. Web. 22 July 2016.  
(5) Heelan, Lisa. "Fetal Monitoring: Creating a Culture of Safety With Informed Choice."  The Journal  
of Perinatal Education J Perinat  Educ  22.3 (2013): 156- 65. Web. 
(6) Isaranurug, Sirkul, LAdda  Mo-Suwan, and Chanpen Choprepawon. "Differences in Socio- economic  
Status, Service Utilization, and Pregnancy Outcomes between Teenage and Adult  
Mothers."  Journal of the Medical Association of Thai land 89.2 (2006 ): 145- 51. PubMed . Web.  
(7) "Pregnancy Complications." Centers for Disease Control and Prevention, 17 June 2016. Web.  
(8) "What Are the Factors That Put a Pregnancy at Risk?" Eunice Kennedy Shriver National Institute of  
Child Health and Human Development, 17 June 2013. Web. 19 July 2016.  
 